140 related articles for article (PubMed ID: 29704518)
1. Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Li Y; Köpper F; Dobbelstein M
Cancer Lett; 2018 Aug; 428():45-54. PubMed ID: 29704518
[TBL] [Abstract][Full Text] [Related]
2. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
[TBL] [Abstract][Full Text] [Related]
3. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
4. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity.
Köpper F; Bierwirth C; Schön M; Kunze M; Elvers I; Kranz D; Saini P; Menon MB; Walter D; Sørensen CS; Gaestel M; Helleday T; Schön MP; Dobbelstein M
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16856-61. PubMed ID: 24082115
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
Singh RK; Diwan M; Dastidar SG; Najmi AK
Hum Exp Toxicol; 2018 May; 37(5):521-531. PubMed ID: 28629242
[TBL] [Abstract][Full Text] [Related]
7. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
[No Abstract] [Full Text] [Related]
8. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Li J; Wang R; Schweickert PG; Karki A; Yang Y; Kong Y; Ahmad N; Konieczny SF; Liu X
Cell Cycle; 2016; 15(5):711-9. PubMed ID: 26890815
[TBL] [Abstract][Full Text] [Related]
9. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
11. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H
Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932
[TBL] [Abstract][Full Text] [Related]
13. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
[TBL] [Abstract][Full Text] [Related]
14. Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.
Fiore M; Forli S; Manetti F
J Med Chem; 2016 Apr; 59(8):3609-34. PubMed ID: 26502061
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.
Nie X; Chanley MA; Pengal R; Thomas DB; Agrawal S; Smoyer WE
Am J Physiol Renal Physiol; 2018 Apr; 314(4):F602-F613. PubMed ID: 29187369
[TBL] [Abstract][Full Text] [Related]
16. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
Araújo PM; da Silva LP; Esteves da Silva JC
Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
[TBL] [Abstract][Full Text] [Related]
17. High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells.
Kuramitsu Y; Wang Y; Kitagawa T; Tokuda K; Akada J; Tokunaga M; Nakamura K
Anticancer Res; 2015 Jul; 35(7):3861-5. PubMed ID: 26124331
[TBL] [Abstract][Full Text] [Related]
18. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers.
Arora M; Bogenberger JM; Abdelrahman AM; Yonkus J; Alva-Ruiz R; Leiting JL; Chen X; Serrano Uson Junior PL; Dumbauld CR; Baker AT; Gamb SI; Egan JB; Zhou Y; Nagalo BM; Meurice N; Eskelinen EL; Salomao MA; Kosiorek HE; Braggio E; Barrett MT; Buetow KH; Sonbol MB; Mansfield AS; Roberts LR; Bekaii-Saab TS; Ahn DH; Truty MJ; Borad MJ
Hepatology; 2022 Jan; 75(1):43-58. PubMed ID: 34407567
[TBL] [Abstract][Full Text] [Related]
19. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Song B; Liu XS; Rice SJ; Kuang S; Elzey BD; Konieczny SF; Ratliff TL; Hazbun T; Chiorean EG; Liu X
Mol Cancer Ther; 2013 Jan; 12(1):58-68. PubMed ID: 23188630
[TBL] [Abstract][Full Text] [Related]
20. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
